搜尋
GSK plc
GSK添加自選
51.100USD
-0.970-1.86%
收盤 06/24, 16:00（美東）報價延遲15分鐘
103.60B總市值
13.17本益比TTM
關鍵數據
52.150今開
52.200最高
3.67M成交量
13.17本益比TTM
9.92本益比動
--股利TTM
0.18%換手率
52.070昨收
51.015最低
103.51M成交額
31.49本益比靜
4.39市淨率
0.00%股息率 TTM
10.56%ROA
61.69552週最高
0.97量比
3.29B淨利潤
2.03B總股本
3.8800每股盈餘TTM
0.38Beta
37.35%ROE
35.45052週最低
2.28%振幅
75.54%毛利率
103.60B總市值
1.02回報/風險
1.09%風險率
TradingKey GSK plc股票評分
單位: USD 更新時間: 2026-06-24操作建議
GSK plc當前公司基本面數據相對穩定，增長潛力很大。當前估值合理，在藥品行業排名60/157位。機構持股佔比非常高，近一月多位分析師給出公司評級為持有。最高目標價為51.90。中期看，股價處於平穩狀態。近一個月，市場表現一般，但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
GSK plc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
中性
GSK plc亮點
亮點風險
GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
利潤高增長
公司淨利潤處於行業前列，最新年度總收入43.02B美元
高分紅
公司屬於高分紅公司，最新股息支付率96.66%
穩定分紅
公司5年內持續分紅，最新股息支付率96.66%
估值低估
公司最新PE估值13.17，處於3年歷史低位
機構減倉
最新機構持股393.46M股，環比減少5.63%
布蘭德斯投資公司持倉
明星投資者布蘭德斯投資公司持倉，最新持倉8.04M股
分析師目標
基於
9
分析師
持有
評級
51.901
目標均價
+2.43%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
GSK plc簡介
GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
公司代碼GSK
公司GSK plc
CEOWaterhouse (Deborah)
網址https://www.gsk.com/
相關品種
+0.90%
+0.82%
+0.83%
+0.08%
+0.88%
-0.14%
+1.27%
-0.02%
+0.09%
-2.71%
+1.45%
-0.89%
-0.65%
+0.41%
0.00%
+0.87%
+1.80%
-0.11%
-0.76%熱門品種
69.344
-0.415 (-0.59%)
293.080
-1.220 (-0.41%)
199.000
-1.040 (-0.52%)
3978.690
-20.050 (-0.50%)
643.830
-26.920 (-4.01%)
1914.460
-49.140 (-2.50%)
1048.510
-3.260 (-0.31%)
345.290
-0.840 (-0.24%)
60713.860
-212.140 (-0.35%)
375.530
-6.080 (-1.59%)
常見問題
GSK plc(GSK)的當前股價是多少？
GSK plc(GSK)的當前股價是 51.10。
GSK plc 的股票代碼是什麼？
GSK plc的股票代碼是GSK。
GSK plc股票的52週最高點是多少？
GSK plc股票的52週最高點是61.70。
GSK plc股票的52週最低點是多少？
GSK plc股票的52週最低點是35.45。
GSK plc的市值是多少？
GSK plc的市值是103.60B。
現在GSK plc(GSK)的股票是買入、持有還是賣出？
根據分析師評級，GSK plc(GSK)的總體評級為signal_hold，目標價格為51.90。
GSK plc(GSK)股票的每股收益（EPS TTM）是多少
GSK plc(GSK)股票的每股收益（EPS TTM）是3.72。
